Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17331292 | 1.00 | NR1H2 (0.56) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL25626705 | 0.87 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL19985698 | 0.87 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL14828708 | 0.87 | NR1H2 (0.45) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL28576704 | 0.86 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL16453661 | 0.86 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL13390672 | 0.86 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL21369480 | 0.86 | NR1H2 (0.44) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL8225670 | 0.86 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3TSHR | |
| SCHEMBL1717751 | 0.86 | NR1H2 (0.55) | NR1H2CHRM2CHRM1CHRM3TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| WO-2024040235-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9868745-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-01-16 | — | — | US | disclosed |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-28 | — | — | US | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9809600-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-11-07 | — | — | US | disclosed |
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-8921341-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2013-11-21 | — | — | US | disclosed |
| US-8575135-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | NR1H2 2557/4885CHRM2 4881/4885CHRM1 4856/4885 |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20130309196-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20180186806-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20140112885-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20170369502-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | NR1H2 5/4885CHRM2 2714/4885CHRM1 1855/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | NR1H2 2935/4885CHRM2 4866/4885CHRM1 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.